ArticleCancer reports (Hoboken, N.J.)2022
Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer.
Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation.International journal of molecular sciences · 2026Review
- The estimated dose of radiation to immune cells predicts lymphopenia and reveals technique-Dependent immune sparing in postoperative radiotherapy for early esophageal cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Predictive Role of Pre-Radiotherapy D-Dimer and Inflammatory Markers in Monitoring Outcomes After Treatment in Hormone-Positive Breast Cancer: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2.Cancer medicine · 2025Review
- Influencing factors of lymphopenia after conventional fractionated whole-breast radiotherapy following breast-conserving surgery for early breast cancer: a retrospective study.Frontiers in oncology · 2025Article
- Lymphopenia associated with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases.Scientific reports · 2024Article
- The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer.Translational lung cancer research · 2024Article
- Lymphocytopenia following adjuvant radiotherapy for breast cancer.Precision radiation oncology · 2024Article
- Effect of Radiation Therapy on Composition of Lymphocyte Populations in Patients with Primary Breast Cancer.Journal of personalized medicine · 2023Article
- Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer.Cancer reports (Hoboken, N.J.) · 2022Article
- Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer.Frontiers in oncology · 2022Article
- Dosimetric Effect of Thymus on Radiation-Induced Lymphopenia in Breast Cancer Patients Who Received Adjuvant Radiotherapy.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphopenia can decrease immune function of the host and is a known risk factor for poor prognosis in malignant tumors. Radiation induced lymphopenia was common in patients with breast cancer and was also reported to have a negative effect on long-term outcome.
aimsLymphopenia may be associated with baseline immune status before radiotherapy (RT). This study aimed to explore the rate and risk factors of lymphopenia before start of the adjuvant RT in patients with breast cancer.
methodsPatients with invasive breast cancer treated from March 2015 to February 2020 and with peripheral lymphocyte counts (PLC) available within 7 days from the beginning of RT were eligible for this study. Data were presented as mean and 95% confidence interval unless otherwise specified. The risk factors of low PLC before RT were identified using univariate and multivariable linear regressions.
resultsA total of 1012 consecutive patients met the study criteria. The mean PLC before RT commencement was 1.58*10
conclusionsPatients with breast cancer might have lymphopenia from prior chemotherapy at the start of adjuvant RT which could have negative effect on long-term outcome. It is also noted that most of the patients with HR+/HER2-, early-stage breast cancer were treated with aggressive chemotherapy without knowing the risk of chemotherapy induced lymphopenia. Future study on predictive or prognostic multigene assays is warranted to avoid unnecessary chemotherapy and subsequent lymphopenia in patients with low risk breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.